Improvement of Cardiac Function in Thalassemia major Treated with L-Carnitine
Authors:
- Amal El-BeshlawyAmal El-Beshlawy
- Lamis RagabLRLamis Ragab
- Alia Abdel FattahAFAlia Abdel Fattah
- Ilham Youssry IbrahimIIIlham Youssry Ibrahim
- Mona HamdyMHMona Hamdy
- Ali MakhloufAMAli Makhlouf
- Elie AounEAElie Aoun
- Victor HoffbrandVHVictor Hoffbrand
- Ali TaherAli Taher
- 1 March 2004
- journal article
- clinical trial
- Published by S. Karger AG in Acta Haematologica
- Vol. 111 (3) , 143-148
Abstract
Introduction: Heart disease secondary to chronic anemia and hemosiderosis remains the major cause of morbidity and mortality in thalassemic patients. Chronic anemia and the tissue hypoxia it induces impair free fatty acid oxidation and ATP production in myocardial cells. The use of L-carnitine, a butyric acid derivative, may help overcome some of these defects. Objective: To investigate the effect of L-carnitine therapy on cardiac function in thalassemia major patients. Materials and Methods: Cardiac function was evaluated in 30 patients attending our clinic. The mean (±SD) age was 15.87 ± 3.19 years. The studies we performed included echocardiography, Doppler and multigated equilibrium radionuclide angiography (MUGA). Systolic and diastolic function was evaluated before starting L-carnitine treatment and after 6 months of oral L-carnitine (50 mg/kg/day). Results: Echocardiography studies revealed no significant changes in systolic and diastolic function after L-carnitine therapy (p > 0.05). Analysis of the data taken by MUGA performed in 20 of the patients, however, showed a significant improvement of diastolic function after 6 months of L-carnitine therapy. The mean peak filling rate (end-diastolic volume/s) increased from 3.15 ± 1.06 to 3.61 ± 1.68 (p < 0.03). The time to peak (during filling) decreased significantly from 143.45 ± 42.04 to 117.70 ± 24.40 s (p < 0.02). Systolic function showed a significant increase in the left ventricular ejection fraction from 58.25 ± 9.92 to 63.95 ± 10.11% (p = 0.0001). Conclusion:L-Carnitine may be an effective drug for improving the cardiac status of thalassemic patients. MUGA is the most accurate technique of those used here for assessing left ventricular function in these patients.Keywords
This publication has 5 references indexed in Scilit:
- Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemiaThe Lancet, 2002
- THE INFLUENCE OFl-CARNITINE SUPPLEMENTATION ON HEMATOCRIT AND HEMOGLOBIN LEVELS IN PATIENTS WITH END STAGE RENAL FAILURE ON CAPDRenal Failure, 2002
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: A combined M-mode, two-dimensional, and Doppler echocardiographic studyAmerican Heart Journal, 1992